The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study
Patricia A.M. Kracht
Faydra I. Lieveld
Linde Amelung
Carina J.R. Verstraete
Eveline P. Mauser-Bunschoten
Joep de Bruijne
Peter D. Siersema
Andy I.M. Hoepelman
Joop E. Arends
Karel J. van Erpecum
10.6084/m9.figshare.6866390.v1
https://adisjournals.figshare.com/articles/figure/The_Impact_of_Hepatitis_C_Virus_Direct-Acting_Antivirals_on_Patient-Reported_Outcomes_A_Dutch_Prospective_Cohort_Study/6866390
<p></p><p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found <a href="https://link.springer.com/article/10.1007/s40121-018-0208-z">here</a><b>.</b> </p>
<p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âmailto:adisrapidplus@springer.comâ"><b>adisrapidplus@springer.com</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>• Slide decks</p>
<p>• Videos and animations</p>
<p>• Audio abstracts</p>
<p>• Audio slides</p><br><p></p>
2018-08-02 08:41:49
Adherence
Beliefs about medicines
Direct-acting antivirals
Health-related quality of life
Hepatitis C virus
Karnofsky performance status